id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-255460-r5p5helx	Aggarwal, Sadhna	Drug repurposing for breast cancer therapy: Old weapon for new battle	2019-09-21		.txt	text/plain	7318	420	42	A phase III clinical trial 'Breast Cancer Trial of Oral Everolimus-2 (BOLERO-2)' that included everolimus in combination with exemestane was successfully completed in 2012 leading to the approval of everolimus by US FDA for the treatment of HR + , HER2 − advanced metastatic cancers that are resistant to letrozole or anastrazole [125, 126] . Docetaxel and paclitaxel are used as neoadjuvant or adjuvant therapy as single agent or in combination with other chemotherapeutic agents for the treatment of early, advanced and metastatic breast cancer in pre-and postmenopausal women. We thus conclude that comprehensive approach of selecting the most appropriate gene-protein-pathway-target-drug modeling via integration of system biology and bioinformatics holds the high potential of providing more efficient, safer and cost-effective chemotherapeutics for treatment of even the most stringent forms of breast cancer (metastatic and triple negative).	./cache/cord-255460-r5p5helx.txt	./txt/cord-255460-r5p5helx.txt